THX Pharma
ALTHX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €4,934 | €8,690 | €9,301 | €24,372 |
| - Cash | €714 | €1,199 | €2,105 | €5,520 |
| + Debt | €2,871 | €3,643 | €4,889 | €5,327 |
| Enterprise Value | €7,091 | €11,134 | €12,085 | €24,179 |
| Revenue | €2,283 | €296 | €415 | €1 |
| % Growth | 670.5% | -28.6% | 68,819.9% | – |
| Gross Profit | -€334 | -€4,639 | €83 | -€8,822 |
| % Margin | -14.6% | -1,565.4% | 20% | -1,465,443.5% |
| EBITDA | -€2,530 | -€7,387 | -€5,925 | -€8,672 |
| % Margin | -110.8% | -2,492.9% | -1,428.1% | -1,440,519.1% |
| Net Income | -€1,765 | -€6,828 | -€6,567 | -€8,150 |
| % Margin | -77.3% | -2,304.2% | -1,582.8% | -1,353,889.4% |
| EPS Diluted | -0.21 | -0.88 | -1.23 | -1.66 |
| % Growth | 76.1% | 28.5% | 25.9% | – |
| Operating Cash Flow | -€3,369 | -€6,358 | -€5,374 | -€6,250 |
| Capital Expenditures | -€33 | -€44 | -€41 | -€151 |
| Free Cash Flow | -€3,401 | -€6,402 | -€5,415 | -€6,400 |